(Q31064623)

English

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab (English)

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

phase III clinical trial

0 references

0 references

author name string

Carlo Pincelli

1

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Eric Henninger

2

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Florence Casset-Semanaz

3

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

publication date

21 September 2006

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Archives of Dermatological Research

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

298

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

7

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

329-338

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

https://scigraph.springernature.com/pub.10.1007/s00403-006-0694-9

0 references

Alefacept: a safety profile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

Clinical considerations of efalizumab therapy in patients with psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

Off-label uses and side effects of infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

21 June 2018

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

25 November 2018

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

25 November 2018

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1705535

25 November 2018

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of treatment modalities for psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17021768

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00403-006-0694-9

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31064623&oldid=1545817443"